Aurinia Pharmaceuticals Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated November 4, 2016, reports on the interim period ended September 30, 2016. The filing incorporates by reference the Interim Condensed Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) for the third quarter of 2016. The registrant is a foreign private issuer filing under Form 40-F.
Key Financial Metrics
The provided text contains only the cover page and exhibit index of the Form 6-K. It does not include the actual financial statements or MD&A content. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this source text.
Material Changes
The filing text does not provide data to compare current period performance against prior comparable periods. No material changes can be summarized from the provided content.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, risk factors, and contingencies are contained within Exhibit 99.2 (MD&A), which is referenced but not included in the input text. Therefore, no specific outlook or risk details can be extracted.
Investor Verification Checklist
- Verify the full content of Exhibit 99.1 (Interim Condensed Consolidated Financial Statements) for actual revenue and cash flow figures.
- Review Exhibit 99.2 (MD&A) for management's discussion of clinical trial progress, regulatory status, and liquidity outlook.
- Confirm the status of the Registration Statement on Form F-10 (File No. 333-206994) referenced in the filing.
- Check for any subsequent filings that may update the financial position as of September 30, 2016.